Celularity Inc. Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
Celularity Inc. (CELU) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of $13.45 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-04-30
- Celularity Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $3.69M, a 31.54% decline year-over-year.
- Celularity Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $822.00K, a 79.84% decline year-over-year.
- Celularity Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-06-30 was $6.23M, a 213.18% increase year-over-year.
- Celularity Inc. increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-03-31 was $2.71M, a 131.34% increase year-over-year.
- Celularity Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was $13.45M, a 6.47% increase from fiscal 2024.
- Celularity Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was $12.63M.
- Celularity Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2023 was -$1.13M.
- Celularity Inc. increase (decrease) in other accounts payable and accrued liabilities for fiscal 2022 was -$2.62M.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $3.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $4.52M derived: sum of 2 quarters · filed 2026-04-30 | $10.74M derived: sum of 3 quarters · filed 2026-04-30 | $13.45M 10-K · filed 2026-04-30 | |||
| 2025-09-30 | $822.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $7.05M derived: sum of 2 quarters · filed 2025-11-14 | $9.76M 10-Q · filed 2025-11-14 | $15.15M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2025-06-30 | $6.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $8.94M 10-Q · filed 2025-08-29 | $14.33M derived: sum of 3 quarters · filed 2026-04-30 | $18.41M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2025-03-31 | $2.71M 10-Q · filed 2025-08-29 | $8.11M derived: sum of 2 quarters · filed 2026-04-30 | $12.18M derived: sum of 3 quarters · filed 2026-04-30 | $14.17M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2024-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $9.47M derived: sum of 2 quarters · filed 2026-04-30 | $11.46M derived: sum of 3 quarters · filed 2026-04-30 | $12.63M 10-K · filed 2026-04-30 | |||
| 2024-09-30 | $4.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $6.07M derived: sum of 2 quarters · filed 2025-11-14 | $7.24M 10-Q · filed 2025-11-14 | $4.58M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29 | $3.16M 10-Q · filed 2025-08-29 | $498.00K derived: sum of 3 quarters · filed 2025-08-29 | $1.39M derived: sum of 4 quarters · filed 2025-08-29 | |||
| 2024-03-31 | $1.17M 10-Q · filed 2025-08-29 | -$1.49M derived: sum of 2 quarters · filed 2025-08-29 | -$602.00K derived: sum of 3 quarters · filed 2025-08-29 | -$686.00K derived: sum of 4 quarters · filed 2025-08-29 | |||
| 2023-12-31 | -$2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$1.77M derived: sum of 2 quarters · filed 2025-05-08 | -$1.86M derived: sum of 3 quarters · filed 2025-05-08 | -$1.13M 10-K · filed 2025-05-08 | |||
| 2023-09-30 | $888.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06 | $804.00K derived: sum of 2 quarters · filed 2024-12-06 | $1.53M 10-Q · filed 2024-12-06 | -$7.64M derived: sum of 4 quarters · filed 2024-12-06 | |||
| 2023-06-30 | -$84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07 | $645.00K 10-Q · filed 2024-11-07 | -$8.52M derived: sum of 3 quarters · filed 2024-11-07 | -$7.73M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-03-31 | $729.00K 10-Q · filed 2024-10-16 | -$8.44M derived: sum of 2 quarters · filed 2024-10-16 | -$7.64M derived: sum of 3 quarters · filed 2024-10-16 | -$2.50M derived: sum of 4 quarters · filed 2024-10-16 | |||
| 2022-12-31 | -$9.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | -$8.37M derived: sum of 2 quarters · filed 2024-07-30 | -$3.23M derived: sum of 3 quarters · filed 2024-07-30 | -$2.62M 10-K · filed 2024-07-30 | $4.71M 10-K · filed 2023-03-31 | ||
| 2022-09-30 | $795.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03 | $5.94M derived: sum of 2 quarters · filed 2024-01-03 | $6.55M 10-Q · filed 2024-01-03 | $899.00K derived: sum of 4 quarters · filed 2024-01-03 | |||
| 2022-06-30 | $5.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $5.75M 10-Q · filed 2023-08-14 | $9.08M 10-Q · filed 2022-08-09 | $104.00K derived: sum of 3 quarters · filed 2023-08-14 | $2.72M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $604.00K 10-Q · filed 2023-05-22 | $1.94M 10-Q · filed 2022-05-16 | -$5.04M derived: sum of 2 quarters · filed 2023-05-22 | -$2.42M derived: sum of 3 quarters · filed 2023-05-22 | $75.00K derived: sum of 4 quarters · filed 2023-05-22 | ||
| 2021-12-31 | -$5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$3.03M derived: sum of 2 quarters · filed 2023-03-31 | -$529.00K derived: sum of 3 quarters · filed 2023-03-31 | -$1.80M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $2.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $5.12M derived: sum of 2 quarters · filed 2022-11-10 | $3.85M 10-Q · filed 2022-11-10 | $4.97M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.23M 10-Q · filed 2022-08-09 | $2.35M derived: sum of 3 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$1.27M 10-Q · filed 2022-05-16 | -$149.00K derived: sum of 2 quarters · filed 2022-05-16 | |||||
| 2020-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $184.00K 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | -$939.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |